{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:31:41Z","timestamp":1790389901511,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Tesaro","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"NSGO","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00280-019-03917-z","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T16:02:55Z","timestamp":1564761775000},"page":"791-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1\/ENGOT-OV24"],"prefix":"10.1007","volume":"84","author":[{"given":"Mansoor Raza","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels K.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Mau-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 dePont","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"\u00c5vall-Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Roed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Malander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Br\u00f8sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"issue":"Suppl 1","key":"3917_CR1","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","volume":"27","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Minion LE, Coleman RL (2016) Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol 27(Suppl 1):i33\u2013i39","journal-title":"Ann Oncol"},{"key":"3917_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","volume":"29","author":"MR Mirza","year":"2018","unstructured":"Mirza MR, Pignata S, Ledermann JA (2018) Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol 29:1366\u20131376","journal-title":"Ann Oncol"},{"key":"3917_CR3","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, ENGOT-OV16, NOVA Investigators et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164","journal-title":"N Engl J Med"},{"key":"3917_CR4","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, SOLO2, ENGOT-Ov21 Investigators et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274\u20131284","journal-title":"Lancet Oncol"},{"key":"3917_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, ARIEL3 investigators et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949\u20131961","journal-title":"Lancet"},{"key":"3917_CR6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"3917_CR7","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1200\/JCO.2017.35.15_suppl.5517","volume":"35","author":"MR Mirza","year":"2017","unstructured":"Mirza MR, Monk BJ, Gil-Martin M, Gilbert L, Canzler U, Follana P et al (2017) Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. J Clin Oncol 35(Suppl):5517","journal-title":"J Clin Oncol"},{"key":"3917_CR8","doi-asserted-by":"crossref","unstructured":"Oza AM, Combe P, Ledermann J, Marschner S, Amit A, Huzarski T, et al (2017) Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Ann Oncol 28(Suppl 5):344 Abstract 965P","DOI":"10.1093\/annonc\/mdx372.036"},{"key":"3917_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Gynecologic Oncology Group et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"3917_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20134205","journal-title":"J Clin Oncol"},{"key":"3917_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL et al (2017) Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779\u2013791","journal-title":"Lancet Oncol"},{"key":"3917_CR12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308","journal-title":"J Clin Oncol"},{"key":"3917_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz018","author":"JF Liu","year":"2019","unstructured":"Liu JF, Barry WT, Birrer M, Lee J-M, Buckanovich RJ, Fleming GF et al (2019) Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdz018","journal-title":"Ann Oncol"},{"key":"3917_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jchromb.2016.11.020","volume":"1040","author":"L van Andel","year":"2017","unstructured":"van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L et al (2017) Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 1040:14\u201321","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"Suppl 8","key":"3917_CR15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdy285.142","volume":"29","author":"J Pfisterer","year":"2018","unstructured":"Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F et al (2018) Carboplatin\/pegylated liposomal doxorubicin\/bevacizumab (CD-BEV) vs. carboplatin\/gemcitabine\/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: a prospective randomized phase III ENGOT\/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG). Ann Oncol 29(Suppl 8):332\u2013333","journal-title":"Ann Oncol"},{"key":"3917_CR16","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","volume":"29","author":"JS Berek","year":"2018","unstructured":"Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A et al (2018) Safety and dose modification for patients receiving niraparib. Ann Oncol 29:1784\u20131792","journal-title":"Ann Oncol"},{"key":"3917_CR17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882\u2013892","journal-title":"Lancet Oncol"},{"key":"3917_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10637-017-0451-2","volume":"35","author":"L van Andel","year":"2017","unstructured":"van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L et al (2017) Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs 35:751\u2013765","journal-title":"Invest New Drugs"},{"key":"3917_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-017-3512-5","volume":"81","author":"K Moore","year":"2018","unstructured":"Moore K, Zhang ZY, Agarwal S, Burris H, Patel MR, Kansra V (2018) The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol 81:497\u2013503","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03917-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03917-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03917-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T09:16:14Z","timestamp":1596273374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03917-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3917"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03917-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MRM reports personal fees from AstraZeneca, Biocad, Clovis Oncology, Oncology Venture, Pfizer, Roche, Tesaro, and ZaiLab, and research Grants to his institution from AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, and Tesaro. He is the global clinical lead for the NOVA trial of niraparib and the ENGOT-EN6\/NSGO-RUBY trial of dostarlimab. EA-L reports honoraria from Roche and consulting\/advisory roles for AstraZeneca, Tesaro, Clovis Oncology, and Genmab. MJB declares relationships with Tesaro, Roche, and Clovis. SM reports a grant for lectures from AstraZeneca and an advisory board for Tesaro. LB receives project support from AstraZeneca and is a member of various ovarian cancer expert panels (Tesaro, Clovis Oncology, and AstraZeneca). JM reports personal fees from AstraZeneca, Tesaro, Clovis, Roche, and MSD. TKB, MMS, RdPC, MJ, HR, FN, UL, and KB declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Part 1 was conducted at a single site (Rigshospitalet, Copenhagen) according to the ethical principles of the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, and applicable local regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Before study initiation, the protocol and informed consent form were reviewed by local regulatory and ethics boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}